Larvol Delta - PRIMO-Intratumoral-Tilsotolimod-a-TLR9-Agonist-Together-With-Intratumoral-Ipilimumab-and-Intravenous-Nivolumab-in-Patients-With-Advanced-Cancers

Yervoy (ipilimumab) - BMS

tilsotolimod (IMO-2125) - Aceragen

Opdivo (nivolumab) - BMS

http://clinicaltrials.gov/ct2/show/NCT04270864

Oct 18, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next